MiNK Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INKT and other ETFs, options, and stocks.About INKT
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
CEOJennifer S. Buell
CEOJennifer S. Buell
Employees23
Employees23
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2017
Founded2017
Employees23
Employees23
INKT Key Statistics
Market cap54.97M
Market cap54.97M
Price-Earnings ratio-3.86
Price-Earnings ratio-3.86
Dividend yield—
Dividend yield—
Average volume25.81K
Average volume25.81K
High today$12.37
High today$12.37
Low today$11.70
Low today$11.70
Open price$12.00
Open price$12.00
Volume20.97K
Volume20.97K
52 Week high$76.00
52 Week high$76.00
52 Week low$4.56
52 Week low$4.56
Stock Snapshot
MiNK Therapeutics(INKT) stock is priced at $11.70, giving the company a market capitalization of 54.97M. It carries a P/E multiple of -3.86.
During the trading session on 2025-12-18, MiNK Therapeutics(INKT) shares reached a daily high of $12.37 and a low of $11.70. At a current price of $11.70, the stock is 0.0% higher than the low and still -5.4% under the high.
Trading activity shows a volume of 20.97K, compared to an average daily volume of 25.81K.
The stock's 52-week range extends from a low of $4.56 to a high of $76.00.
The stock's 52-week range extends from a low of $4.56 to a high of $76.00.
People also own
Based on the portfolios of people who own INKT. This list is generated using Robinhood data, and it’s not a recommendation.